INTRODUCTION {#S1}
============

Morphine is commonly used to treat postoperative pain in children, but the provision of effective analgesia is limited by occurrence of serious side effects like respiratory depression (RD). Opioid induced RD has potentially fatal consequences and has been reported to contribute to up to 50% of postoperative respiratory failure events ([@R1]--[@R4]). Twin studies have detected significant heritability for RD (30%) from opioids ([@R5]) which indicates that genetics may play a role in determining susceptibility to RD. We recently reported that variants in certain genes in the morphine response pathway, namely, μ-opioid receptor (*OPRM1*), ATP-Binding Cassette *ABCB1* and Fatty Acid Amide Hydroxylase (*FAAH*), affect morphine clinical outcomes including RD in children ([@R6]--[@R8]).

There is not much known about the effect of genes involved in morphine pharmacokinetics (PK) on morphine clinical outcomes([@R9]) although morphine metabolism in the liver by glucuronidation to morphine 3 glucuronide (M3G) and morphine 6 glucuronide (M6G) is well described ([@R10]). The efflux of morphine glucuronides from the hepatic cell is an ATP-dependent process mediated by the ATP-Binding cassette transporters including *ABCC3* ([@R10]--[@R18]). We recently demonstrated that *ABCC3* variants contribute to variability in morphine, M3G and M6G pharmacokinetics (PK) ([@R19], [@R20]). In this study, we hypothesized that *ABCC3* variants could potentially affect serious morphine clinical outcomes, namely, RD, by altering liver transport of morphine metabolites. The primary aim of the study was to identify associations between common *ABCC3* genotypes and postoperative RD in children undergoing tonsillectomy, and RD causing delayed hospital discharge, as this is an economically relevant outcome associated with increased healthcare costs. We further investigated if the variants involved affected morphine's PK in a younger Tonsillectomy cohort as well as in another independent cohort of older children and adolescents undergoing spine surgery.

Subjects and Methods {#S2}
--------------------

### Study Design and Setting {#S3}

This is a prospective, genotype blinded, clinical observational study in two independent cohorts: children undergoing outpatient adenotonsillectomy ("Tonsillectomy" cohort) and adolescents undergoing spine surgery ("Spine surgery" cohort) which are registered with clinicaltrials.gov, NCT01140724 and NCT01839461 respectively. Both studies were approved by the institutional review board and written informed consent was obtained from parents/18 year old patients and assent obtained when appropriate from children 7--17 years of age before enrollment.

### Participants and Standard Anesthetic Procedures {#S4}

All participants received surgery-specific standard perioperative care, including standardized surgical, anesthetic and postoperative care. In both studies, children were excluded if they or their parents were non-English speaking, allergy to morphine, had developmental delay, liver or renal diseases, or preoperative pain requiring analgesics.

#### Tonsillectomy cohort {#S5}

Children 6 -- 15 years with an American Society of Anesthesiologists (ASA) physical status 1 or 2 scheduled for tonsillectomy or adenotonsillectomy for recurrent tonsillitis, adenotonsillar hypertrophy or obstructive sleep apnea (OSA), were recruited for the study on the day of surgery. The child was considered to have OSA if he/she had a history of sleep disordered breathing with history of snoring plus respiratory pauses during sleep lasting more than 10 seconds or daytime drowsiness, or "yes" to 8 or more of the 22 questions in the Pediatric Sleep Questionnaire (PSQ)([@R21], [@R22]). Anesthesia was induced using sevoflurane followed by a propofol (2 mg/kg) bolus to facilitate endotracheal intubation. Anesthesia was maintained with sevoflurane without the use of neuromuscular blockade. Patients received standard perioperative care along with one intra-operative intravenous morphine bolus dose of 0.2 mg/kg. Children with OSA received a morphine dose of 0.1 mg/kg. All children receive prophylactic ondansetron (0.1 mg/kg) and dexamethasone (0.1 mg/kg) intraoperatively. Significant postoperative pain measured with facial expression; leg movement; activity; cry; and consolability (FLACC) pain score ≥ 4/10 ([@R25])was managed in the postoperative anesthesia care unit (PACU) with rescue doses of morphine (0.05mg/kg increments). Duration of PACU stay (time to achieve PACU discharge readiness) was defined as the duration in PACU before achieving the following discharge criteria. If a patient required more than 90 minutes to meet PACU discharge criteria following tonsillectomy, it was defined as a prolonged PACU stay.

#### Spine Surgery cohort {#S6}

Children aged 10--18 years of age with a diagnosis of idiopathic scoliosis undergoing spine fusion were recruited. Patients received total intravenous anesthesia during the surgery with propofol and remifentanil, and morphine doses towards the end of surgery to clinically parameters (pain scores and respiratory rate). Postoperatively, they received morphine through patient controlled analgesia (PCA), managed by clinical pain service.

### Clinical Outcome Measures {#S7}

Metrics for opioid-related RD were recorded for each participant in the PACU for the Tonsillectomy cohort and on postoperative day 1 for the Spine Surgery cohort. In our study, we defined clinical RD as a persistent (more than a minute) oxygen desaturation \<90% or respiratory rate \<8 breaths per minute or oxygen desaturation \<94% along with respiratory rate \<10 per minute requiring supplemental oxygen to maintain SpO2 \>94% in the absence of clinically obvious upper airway obstruction. Total morphine dose was total amount of morphine used (in mg/kg) intraoperatively and immediate postoperative period in PACU (Tonsillectomy cohort) and over the 1^st^ postoperative day (Spine Surgery cohort).

### Genotyping (both cohorts) {#S8}

Blood was drawn in the operating room upon intravenous line placement under anesthesia for genotyping. DNA was isolated on the same day and, frozen at −20°C. One previously studied common SNP (rs4793665) was genotyped using TaqMan allelic discrimination system assays (Life Technologies, Applied Biosystems, USA). Genome-wide genotyping was performed on the Illumina Human OMNI-5 genotyping array using the iScan System (Illumina) and Infinium2 chemistry. Genotypes were called using the Gentrain2 algorithm within Illumina Genome Studio. Using PLINK, only 4 samples showed genome-wide calling rate below 95%, suggesting an overall good quality of the samples. To extract SNPs on the *ABCC3* gene, we examined a region on the chromosome 17 spanning 48.71 to 48.77 Mb. This region covers the longest *ABCC3* transcript, and \~2kb upstream and \~1kb downstream of *ABCC3*. Samples with call rates below 90% in the selected region, SNPs with call rates below 95%, minor allele frequency (MAF) lower than 0.05 in AA or Caucasians, or off HWE (p-value 0.0001) were dropped from the analyses ([Figure 1B](#F1){ref-type="fig"}).

Functional consequences of SNPs above were assessed using RegulomeDB ([@R23])(<http://regulome.stanford.edu/index>), with scores ranging from 1 (highly likely functional, through 2a/b (likely to affect binding of regulatory factors to DNA), to 5/6 (unlikely regulating binding).

### Analysis of Genetic association with RD/Prolonged RD in the Tonsillectomy cohort {#S9}

Prior to analyses, quality of the data was checked. Characteristics of the patients and properties of the SNPs were examined in African American and Caucasian children respectively. Logistic regressions were performed to analyze binary outcomes RD and Prolonged RD. Prior to evaluation of *ABCC3* variants, the effects of total morphine, age, sex, BMI z scores and OSA were tested using the Statistical Analysis Software (SAS), version 9.3. To select the best fitting model, log likelihood, Akaike and Bayesian Information criterion were compared. Co-variables that significantly improved model fitting (p\<0.05) were retained for subsequent genetic analyses. Using PLINK, each of the 42 SNPs was then tested in an additive model, in which the genotypes were recoded to 0, 1 and 2 according to the number of minor alleles and tested as continuous variables. To account for the population structures, we performed principal component analysis (PCA) on 218 ancestry informative markers (AIMs) as we have done with previous analyses ([@R7], [@R8]). A marked drop in the percentage of variation explained by PCs was observed after PC1 and 2. Therefore, the first two PCs, as well as self-reported race, were included in all the logistic models. In this study, we tested the genetic associations of 42 SNPs with two clinical outcomes.

#### Pharmacokinetic Sampling {#S10}

Serial blood samples were obtained to quantify morphine, M3G and M6G systemic concentration. A pre-dose sample was obtained before IV morphine bolus dose from an IV line. Further samples were obtained using independent venous needle sticks 0--5 min, 10--15 min and 30--45 min after the first bolus morphine intravenous dose. For spine cohort, additional samples were drawn at 60--120 minutes, and 1--3 samples over the first 24 hours if the child had respiratory depression (as defined above).

#### Pharmacokinetic Analysis {#S11}

Morphine and its active metabolites, M3G and M6G, were quantified in EDTA plasma using a validated liquid chromatography tandem mass spectrometry assay. Details of the analytical methods have been described elsewhere ([@R24]). The reliable limits of quantification were 0.25--1000 ng/ml (r^2^ \> 0.99) for morphine, and 1--1000 ng/ml (r^2^ \> 0.99) for both M3G and M6G. Total imprecision was less than 15%. The inter-day accuracy was within 85--115%.

#### Morphine Pharmacokinetic Model Development and Evaluation {#S12}

A population pharmacokinetic model was developed for morphine using nonlinear, mixed effects modeling approach (NONMEM; version 7.2, ICON Dev. Soln., MD, USA) with PsN-Toolkit (version 3.5.3) as the interface. Data pre-processing, post-processing and visualization were performed using the statistical package R (version 2.15). A two compartment structural model, parameterized in terms of clearance (*CL)*, central volume of distribution (*V~1~*), inter-compartmental clearance (Q), peripheral volume (*V~2~*) of distribution, was used to describe the morphine concentration--time profiles. A delay compartment was incorporated in the model to describe the delay metabolite formation. The metabolite pharmacokinetics was modeled using an additional compartment for each metabolite and was parameterized in terms of formation clearance (*FCL~M3G~* & *FCL~M6G~*), volume of distribution (*V~M3G~* & *V~M6G~*) and clearance (*CL~M3G~* & *CL~M6G~*). For further details about the PK model development for both cohorts, please see [Supplementary Information](#SD1){ref-type="supplementary-material"} section.

#### Pharmacokinetic-Pharmacogenetic Analysis {#S13}

Potential pharmacogenetic covariate relationships were initially examined with plots of post hoc variability (η) in morphine and metabolite clearance variations with genotypes. Genetic covariate analysis was performed on selected *ABCC3* SNPs found to have significant association with clinical outcomes to investigate if similar associations were observed in morphine pharmacokinetics. Genetic covariate analysis was performed using NONMEM by incorporating the genotype as categorical covariates. The significance of a genotype as a covariate in morphine PK was determined a decrease in the OFV of 3.84 (p\<0.05, degree of freedom =1) between nested models.

### Power analysis {#S14}

To test our power to detect differences by genetic variant, we used Quanto to vary the minor allele frequency (MAF) from 0.1 to 0.5. After adjusting for multiple testing with Bonferroni (0.05/42 = 0.0012), a two-sided alpha of 0.0012 will be needed to detect significant differences. Assuming that variables are normally distributed (with a mean of 0 and a standard deviation of 1.0), we have 80% power to detect a variant that explains as little as 3% of the phenotypic variance (effect sizes 0.24 to 0.41 standard deviation units across a range of MAF).

RESULTS {#S15}
=======

Demographics and clinical characteristics {#S16}
-----------------------------------------

A consort diagram illustrates enrolled study subjects in the Tonsillectomy cohort ([Figure 1A](#F1){ref-type="fig"}). Participants were primarily self-identified as Caucasian. Compared to Caucasian children, African American (AA) children were slightly heavier and had significantly higher obstructive sleep apnea (OSA) frequencies ([Table 1](#T1){ref-type="table"}). Although AA children required higher total morphine dose, the incidences of RD and Prolonged RD (RD leading to prolonged Post anesthesia Care Unit (PACU) stay) were comparable between AA and Caucasian children ([Table 1](#T1){ref-type="table"}). The spine cohort included 67 non-obese children (70% females/79% Caucasian) aged 14.6 ± 1.9 years, weighing 59.2 ± 16.6 kg.

*ABCC3* Single Nucleotide Polymorphisms (SNPs) description {#S17}
----------------------------------------------------------

A total of 127 Single Nucleotide Polymorphisms (SNPs) in the *ABCC3* gene were genotyped by Illumina Human Omni 5 array techniques and one SNP by Taqman assay. Of the 128 SNPs, 42 had minor allele frequency (MAF) of 5% or more in both AA and Caucasian children ([Figure 1B](#F1){ref-type="fig"}). Since these polymorphisms were in Hardy Weinberg equilibrium (HWE) at alpha=0.0001 level, all 42 SNPs were included in genetic association analyses.

Non-genetic covariates associated with clinical outcomes {#S18}
--------------------------------------------------------

Before testing the genetic effect, we evaluated the effects of age, sex, total morphine requirement, obstructive sleep apnea (OSA), and body mass index (BMI) z score on RD and Prolonged RD. Significant effects of total morphine dose and BMI z score were detected (p\<0.05). No significant OSA effect was detected. Therefore, in subsequent genetic models in which single polymorphism associations were tested, total morphine and BMI z score were included as co-variates. As all analyses were performed with AA and Caucasian children combined, in order to reduce the risk of spurious association due to racial differences, we included race as a co-variate in all statistical modeling.

Genetic association with clinical outcomes {#S19}
------------------------------------------

Although there was no statistically significant association between tested *ABCC3* polymorphisms and RD, a clinically severe form of RD leading to prolonged stay in the PACU (Prolonged RD) had significant associations with 7 polymorphisms of *ABCC3* localized to a region between 48731392 to 48744612 bp on Chromosome 17 ([Table 2](#T2){ref-type="table"}) ([Figure 2](#F2){ref-type="fig"}). Two adjacent polymorphisms, *rs739923* and *rs4148412*, showed the most significance ([Table 2](#T2){ref-type="table"}). For *rs739923*, one copy of the G allele increased odds of Prolonged RD 3.7 times (95% CI 1.47--9.09, p=0.005); for *rs4148412*, one copy of the A allele increased the odds 2.4 times (95%CI 1.28--4.37, p=0.0061) ([Table 2](#T2){ref-type="table"}). Compared to mean duration to achieve PACU discharge readiness (duration of PACU stay) for the entire Tonsillectomy cohort (n=316) of 87.1±36.7 minutes, children with high risk genotypes for Prolonged RD stayed in PACU about 50 minutes longer (p\<0.05). The duration to achieve PACU discharge readiness in children with AA genotype of rs4148412 was 138.3 ± 46.8 minutes and with GG genotype of rs739923 was 154 ± 54.9 minutes.

*ABCC3* Single Nucleotide Polymorphisms and Morphine Pharmacokinetics {#S20}
---------------------------------------------------------------------

Polymorphisms identified in a particular region of the *ABCC3* gene (Chr17: 48731392 to 48744612) for association with Prolonged RD, and another earlier polymorphism that we reported to have association with morphine PK, *rs4793665* ([@R19]), were tested for association with morphine and metabolite formation clearances in this Tonsillectomy cohort as well as in another independent Spine Surgery cohort. *ABCC3* rs4793665 CC genotype tonsillectomy and spine surgery subjects appeared to have higher mean formation clearances of M3G and M6G (*FCL~M3G~* and *FCL~M6G~*) than CT and TT genotypes combined based on variation of post-hoc individual estimates across genotypes ([Figure 3](#F3){ref-type="fig"}). In both cohorts, rs4793665 genotypes were found to be significant covariate for M6G formation (*FCL~M6G~*; Change in Objective Function Value (dOFV) = −7.73 and −8.10 for Tonsillectomy cohort and Spine Surgery cohort respectively, [Table 3](#T3){ref-type="table"}) with CC genotypes having 51 % (Tonsillectomy cohort; 95% CI \[4.2; 97%\]) and 37% (Spine surgery cohort; 95% CI \[11%; 63%\]) higher formation respectively than others ([Table 4](#T4){ref-type="table"}). Similarly, rs4793665 CC genotypes was a significant covariate for M3G formation (*FCL~M3G~*; (dOFV) = −16.46 and −9.1 for tonsillectomy and spine surgery cohorts respectively, [Table 3](#T3){ref-type="table"}) with CC genotypes having 54% (95% CI (21%;100%)) in the Spine Surgery cohort and 55% 95% CI (18%;92%)) in the Tonsillectomy cohort ([Table 4](#T4){ref-type="table"}).

Subjects with *ABCC3* rs4148412 AA genotype had higher mean *FCL~M3G~* and *FCL~M6G~* than subjects with AG and GG genotypes combined (Figure 5). In the tonsillectomy study, rs4148412 AA genotypes were found to be significant covariate for *FCL~M3G~* (dOFV= −5.83, [Table 4](#T4){ref-type="table"}) with AA genotypes having 31 % (95% CI (−2%; 65%)) higher M3G formation. Similar trend (dOFV= −3.53, p =0.06) was observed in the spine study with *rs4148412* AA genotypes having higher 45% (95% CI (−4%; 95%)) higher M3G formation. ABCC3 *rs4148412* AA genotype subjects tended to have 25% (Tonsillectomy) and 22% (Spine surgery) higher M6G formation than others, though the association was not significant.

Though rs35364174 GG genotypes had higher (8%) morphine CL than others, there was no significant association with metabolite formations. Across both studies, no other significant genetic covariates for M3G and M6G formation ([Table 3](#T3){ref-type="table"}).

Putative functional consequences of SNPs {#S21}
----------------------------------------

Using RegulomeDB, two of the SNPs are predicted to likely (rs1978153) or somewhat likely (rs61479331) affect binding of regulatory factors to DNA. The SNP rs4793665 was also found to have a RegulomeDB score of 2b, which makes it likely to affect binding.

DISCUSSION {#S22}
==========

In this study of 316 children undergoing tonsillectomy, we found significant associations between common polymorphisms in the *ABCC3* gene and RD leading to prolonged PACU stay. Presence of allele A at *rs4148412* was associated with a 2.4 fold increase in odds ratio (95% CI =1.28--4.37, p=0.0061), and allele G at rs729923 increased the odds ratio for Prolonged RD by 3.7 fold (95% CI 1.47-- 9.09, p=0.0050). Correspondingly, increased formation clearances of M3G and M6G were noted in rs4148412 AA and genotypes rs4973665 CC genotypes (p\<0.05) in this larger tonsillectomy cohort; a similar association was reproduced in the Spine Surgery cohort (p\<0.05). In our Tonsillectomy cohort, children with genetic risk for Prolonged RD (AA genotype of *ABCC3* rs4148412 and GG genotype of rs739923) stayed about 50 minutes longer in PACU compared to the entire cohort's mean PACU stay, which implies increased PACU costs of ≈ US \$392 in our hospital. This is the first time a clinically and economically relevant outcome: opioid related postoperative respiratory depression resulting in prolonged hospital stay, is associated with *ABCC3* variants and simultaneously supported by variant effects on morphine metabolite formation in two independent surgical cohorts, highlighting a novel pathway with validating biological evidence.

The *ABCC3* gene (also known as Multidrug Resistance Protein 3/*MRP3*) codes for a sinusoidal transporter with high expression in liver cells ([@R25], [@R26]). *ABCC3* transporters are known to transport organic compounds conjugated to glucuronate ([@R27]--[@R29]). Evidence for *ABCC3* mediated transport of morphine glucuronides comes from vesicular uptake experiments; insect cells overexpressing *MRP3* were found to transport M3G and M6G ([@R18]) and *Mrp3*-null mice were unable to excrete M3G from the liver into the bloodstream resulting in 50-fold reduction in plasma M3G levels. The fact that morphine conjugation in hepatocytes is followed by transport of the metabolites across their sinusoidal membrane, where *ABCC3* is located([@R30]), prompted us to study the role of this gene in morphine outcomes and morphine-glucuronide formation clearance. To our knowledge, there are no studies evaluating *ABCC3* variants and morphine effect in humans. In mice, the absence of *Mrp3* was shown to decrease anti-nociceptive potency of injected M6G in *MRP3 ^(−/−)^* mice and affect M6G PK ([@R18]). In humans, the antagonizing effects of M3G on morphine-induced analgesia however were noted to be weak.

In this study, we have identified a region in the *ABCC3* gene located in chromosome 17 (4871392 and 48744612, spanning 13,221 bp), associated with RD leading to prolonged PACU stay. Seven of 10 SNPs located in this region are associated with this outcome in tonsillectomy patients (p\<0.05). All these polymorphisms are intronic and hence are not known to change the structure of the protein. It is possible that less common exon variants are present in the region that we did not test for associations. However, upon review of the Exome Variant Server database, we did not identify any common (MAF \> 5%) protein changing variants with a predicted functional effect in *ABCC3*. As we have mentioned in the results section and [Table 2](#T2){ref-type="table"}, RegulomeDB scores for rs1978153 and rs61479331 in this region and rs4793665, indicate they may have a high likelihood of affecting binding of regulatory factors to DNA. Another possible explanation arises from a limited body of knowledge regarding variations at noncoding regulatory sequences known to contribute to variable expression of genes ([@R31], [@R32]). It is known that the genome comprises a large number of noncoding DNA regulatory elements, including silencers, insulators, and enhancer regions, that play important regulatory roles in maintaining gene expression programs ([@R33], [@R34]). Enhancers have emerged as key cis-regulatory elements that can affect gene transcription independent of their orientation or distance. On examining the region closely, we find that it is close to the posttranslational modification of histone H3 (H3K27AC --acetylation of lysine 27) which is associated with both active promoters and enhancers ([@R35], [@R36]). Since variants that affect chromatin at distal regulatory sites frequently also direct changes in chromatin and gene expression at associated promoters ([@R31]), it is postulated that the variants at this critical region of *ABCC3* affect gene expression in some yet unknown way (<https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&position=chr17%3A48731392-48744612&hgsid=422527087_473p6AuZ9wOAcJCUlay6N3C1LB4y>) .

In fact, the majority of distal H3K27ac enrichment was found within introns and the activity of proximal genes was found to correlate positively with distal H3K27ac enrichment in adult liver tissues ([@R37]), providing additional support to our results and hypothesis about the mechanism.

Morphine and metabolite PK from our two independent study cohorts were well described using similar structural PK models which include a central and peripheral compartment for morphine, one distribution compartment for each metabolite and a compartment to account for the delay in the metabolite formation. Model parameters for the morphine PK model were found to be mostly similar in both tonsillectomy and Spine Surgery cohorts ([Table S1](#SD2){ref-type="supplementary-material"}). The ratio of the formation clearance of M3G relative to M6G morphine clearance estimates was found to be 7.2 in the spine surgery population and 9.6 in the tonsillectomy population. This is consistent with other reports indicating that M3G metabolite formation is 7--10 fold higher than M6G formation ([@R38], [@R39]). The small differences in the morphine models from the two studies could be attributed to inter-study variances arising due to differences in (a) population demographics, (b) co-medication and (c) pharmacokinetic sampling strategy.

Earlier, we showed that children with *ABCC3* rs4793665 CC genotype (−211 C/T) had 46% higher M6G formation and 41% higher M3G formation indicating an increased efflux of metabolites into the blood than C/T and T/T genotypes combined([@R19]). These previous findings were reproduced in the spine surgical cohort, where CC genotypes had 37% more M6G and 55% more M3G formation clearance. This *ABCC*3 SNP −211T (rs4793665) is located in the promoter region of the gene and has been reported to alter hepatic mRNA expression ([@R40]) and contribute to lower efflux of morphine glucuronides ([@R41]). Although other studies have not shown a change in mRNA expression ([@R42]), our study shows that it is associated with transformation clearance for M6G. In the current analysis we also found that *ABCC3* rs4148412 AA genotype had higher M3G formation -- this allele was also found to increase Prolonged RD risk by an OR of 2.36 (95% CI=1.28--4.37; p=0.0061). Prior PK studies indicate substantially higher plasma concentrations of the two metabolites (especially M3G) than those of morphine (M3G/morphine: 34; M6G/morphine: 3.9)([@R43]) and this may be why we were unable to detect effects of this polymorphism on M6G formation. Though the genotype was observed to clearly alter the metabolite formation, no significant impact on morphine clearance was observed, which supports the fact that *ABCC3* is not a transporter of morphine, and hence variants would not affect morphine clearance.

One of the limitations of the outpatient tonsillectomy population is the shorter duration of sampling for morphine and metabolite concentrations, as patients were discharged home within 1 to 2 hours after surgery. The sampling period was extended in the Spine Surgery cohort as the patients remain in the hospital after surgery. Another limitation was that we tested association for 42 polymorphisms of *ABCC3* with a relatively small sample size of 316 children, so there is a possibility that some of the associated variants may have been associated by chance. However, for rs4148412, we found association with both the clinical outcome of prolonged PACU stay due to RD and with PK measures, and validation of similar PK association in an independent Spine Surgery cohort. The identification of association using 2 independent outcomes provides validation of our findings. Relatively higher doses of morphine might have contributed to overall higher incidence of RD; however children with certain *ABCC3* genotypes had significantly higher M6G levels and prolonged RD with morphine. Lastly, we did not report associations with clinical outcomes with *ABCC3* for the smaller spine cohort as the current sample size is not statistically robust to make meaningful conclusions. However, these are ongoing studies and will allow us to validate genetic and clinical outcomes associations in the future.

In conclusion, our pediatric tonsillectomy study demonstrates that *ABCC3* variants are associated with postoperative RD leading to prolonged hospital stay. This *ABCC3* genetic association with clinical outcome was supported by a consistent pharmacokinetic association in the Tonsillectomy cohort, which is further validated in an independent Spine Surgery cohort. Prolonged RD besides being a clinically significant problem, has significant potential to increase the cost of care by prolonging postoperative hospital stays. While highlighting potential economic burden, our study also offer possible solutions with preemptive identification of high risk patients and personalized analgesic selection. If children who are genetically predisposed to relatively higher risks of morphine related respiratory depression leading to prolonged hospital stay could be preemptively identified especially preoperatively, clinicians instead of intravenous morphine could potentially use alternative analgesics such as intravenous fentanyl and hydromorphone that are not transported through *ABCC3* transporters. Thus, these findings are novel, clinically important and add to the knowledge of genetic factors that contribute to life-threatening central adverse effects of morphine, moving us a step closer towards safer and more efficient opioid analgesia in vulnerable patients.
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![A. Enrollment consort diagram\
illustrates the flow of enrolled study participants through this clinical trial. Reasons for exclusions, enrolled and analyzed patients are reported. \* Principal Component Analysis using 218 Ancestry Information Markers was done (explained in reference ([@R7])), using Hapmap population as the reference group and principal components PC2 vs. PC1 were plotted (not shown here). The selection of subjects that did not cluster well-- 9 Caucasian and 4 African American (AA) were thus excluded. **B: ABCC3 Polymorphism Selection Diagram** illustrates the selection of polymorphisms based on genome wide and Taqman genotyping for inclusion in genetic association analysis. SNP=Single nucleotide polymorphism. \#Illumina Human OMNI-5 genotyping array using the iScan System (Illumina) and Infinium2 chemistry. RD: Respiratory depression; PACU: Postoperative Anesthesia Care Unit; SNPs: Single Nucleotide Polymorphisms](nihms738442f1){#F1}

![Genetic association of 42 *ABCC3* polymorphisms and clinical outcomes: Respiratory Depression (RD) -- top panel and Prolonged Postoperative Care Unit (PACU) stay due to RD/Prolonged RD (lower panel)\
The y axis shows the −log10 P values and the x axis shows the chromosomal positions of the *ABCC3* polymorphisms (SNPs) on Chromosome 17. The −log10 (p values) of the single SNP association tested in additive models are plotted. The reference line (small dots) shows the −log10 (p value of 0.05) level. In both races consistently several *ABCC3* SNPs between the vertical lines (region between 48731392 to 48744612 bp) showed significant association with prolonged PACU stay due to respiratory depression. The p-values were smoothed using a running median represented by the red line in both plots.](nihms738442f2){#F2}

![Box & Whiskers plots of variation in M3G/M6G formation CL normalized to 70 kg subject with *ABCC3* rs4793665 and rs4148412 genotypes in the Tonsillectomy and Spine Surgery cohorts. Statistical significant differences among genotypes are marked with p\<0.05.](nihms738442f3){#F3}

###### 

Characteristics of participants in tonsillectomy cohort

Age, weight, BMI z score and intra-operative morphine requirement are shown as median and inter-quartile range (IQR), and compared between whites and blacks using Wilcoxon rank sum tests; sex, Obstructive Sleep Apnea (OSA), PACU: Postoperative Care Unit; Respiratory depression and prolonged PACU stay due to respiratory depression are shown as frequencies and proportions, and compared using Pearson's Chi-squared tests.

BMI: Body Mass Index; BMI z scores were calculated using Center for Disease Control (CDC) growth charts.

                                                      Whites (N=267)       Blacks (N=49)        *p* value
  --------------------------------------------------- -------------------- -------------------- -----------
  Age (year)                                          8.4 (7.2, 11.1)      8.8 (7.1, 105)       0.80
  Weight (Kg)                                         33.6 (25.4, 45.3)    34.0 (25.0, 53.8)    0.32
  BMI z scores                                        0.62 (−0.23, 1.59)   0.89 (−0.01, 2.04)   0.09
  Intra-operative morphine requirement (mg/kg)        0.20 (0.17, 0.22)    0.19 (0.15, 0.20)    0.41
  Total morphine requirement (mg/kg)                  0.24 (0.20, 0.29)    0.28 (0.20, 0.34)    0.011
  Sex                                                                                           0.32
   Male                                               135 (51%)            21 (43%)             
  OSA                                                                                           0.002
   Yes                                                111 (42%)            32 (65%)             
  Respiratory Depression                                                                        0.38
   Yes                                                75 (28%)             17 (35%)             
  Prolonged PACU stay due to Respiratory Depression                                             0.79
   Yes                                                24 (9%)              5 (10%)              

###### 

Association of prolonged postoperative care unit stay due to morphine induced respiratory depression with polymorphisms in an identified critical region of *ABCC3* gene

                                  Illumina ID   rs\#         Location    Risk allele (%)   Protective allele (%)   P value association   OR (95% CI)         Putative function/ RegulomeDB score
  ------------------------------- ------------- ------------ ----------- ----------------- ----------------------- --------------------- ------------------- -------------------------------------
  Prolonged PACU Stay due to RD   kgp9079579    rs35364174   48731392    G (0.497)         A (0.503)               **0.0496**            1.80 (1.00, 3.24)   Intron/5
                                  rs4148412     48733815     A (0.382)   G (0.618)         **0.0061**              2.36 (1.28, 4.37)     Intron/5            
                                  rs739923      48735774     G (0.750)   A (0.250)         **0.0050**              3.70 (1.47, 9.09)     Intron/4            
                                  rs733392      48736403     G (0.756)   A (0.244)         **0.0239**              2.63 (1.14, 5.88)     Intron/5            
                                  rs1978153     48737861     C (0.627)   G (0.373)         **0.0152**              2.27 (1.18, 4.35)     Intron/**2b**       
  kgp388163                       rs2301837     48738266     G (0.905)   A (0.095)         0.4262                  1.56 (0.84, 4.55)     intron              
  kgp3814620                      rs7216383     48739543     A (0.709)   G (0.291)         **0.0316**              2.22 (1.08, 4.76)     Intron/4            
  kgp2507665                      rs61479331    48740116     A (0.729)   C (0.271)         0.0524                  2.08 (0.99, 4.35)     Intron/**3a**       
                                  rs16949202    48743275     A (0.867)   G (0.133)         0.8366                  1.10 (0.46, 2.63)     intron              
  kgp12280761                     rs886493      48744612     C (0.535)   A (0.465)         **0.0134**              2.27 (1.18, 4.35)     Intron/5            

Note: Effects were shown as odds ratio (OR) and 95% CI for prolonged postoperative care unit (PACU) stay due to respiratory depression (RD) in the tonsillectomy cohort. OR indicated the odds ratio when minor allele (races combined) increased by one copy. Putative functional consequences of SNPs above have been also assessed using RegulomeDB (<http://regulome.stanford.edu/index>), with scores ranging from 1 (highly likely functional, through 2a/b (likely to affect binding of regulatory factors to DNA), to 5/6 (unlikely regulating binding).

###### 

Pharmacokinetic/Pharmacogenetic association of *ABCC3* SNP genotypes with morphine clearance and metabolite formation clearances in tonsillectomy and spine cohorts.

  SNP           Tests        N              Morphine\*   Morphine-3-Glucuronide Formation\*   Morphine-6-Glucuronide Formation\*                                           
  ------------- ------------ -------------- ------------ ------------------------------------ ------------------------------------ ------------- ------------ ------------ ------------
  kgp9079579    rs35364174   GG vs. AG+AA   216          67                                   −**4.09**                            −3.713        −0.08        −0.954       −0.02
                rs4148412    AA vs. AG+GG   216          66                                   −0.686                               −**5.833**    −3.53        −2.111       −1.54
                rs739923     AA vs. AG+GG   219          66                                   −0.353                               −2.123        −0.35        −0.921       −0.011
                rs733392     AA vs. AG+GG   217          62                                   −2.102                               −0.82         −0.24        −1.558       −0.211
                rs1978153    GG vs. GC+CC   219          67                                   −0.817                               −0.531        −0.06        −0.325       −0.81
  kgp388163     rs2301837    AA vs. AG+GG   216          67                                   −1.185                               −0.095        −0.001       −0.008       −0.79
  kgp3814620    rs7216383    GG vs. AG+AA   219          67                                   −1.19                                −2.303        −0.004       −1.263       −0.301
  kgp2507665    rs61479331   CC vs. AC+AA   219          67                                   −1.901                               −0.801        −0.006       −1.263       −0.188
                rs16949202   GG vs. AG+AA   216          67                                   −0.109                               −0.956        −0.07        −0.01        −3.278
  kgp12280761   rs886493     AA vs. AC+CC   218          N/A                                  −0.22                                −0.011        N/A          −0.311       N/A
                rs4793665    CC vs. CT+TT   220          67                                   −1.727                               −**16.464**   −**9.102**   −**7.726**   −**8.096**

ΔOFV = OFV~Cov~ - OFV~NoCov~

ΔOFV \< −3.84 was considered to be statistically significant and are highlighted in bold.

N = number of patients in the cohort for which the genetic data was available

Vs. = versus

T&A: Tonsillectomy Cohort; Spine: Spine Surgery Cohort

###### 

Key *ABCC3* genotype effects on morphine clearance and metabolite formation clearances in both cohorts

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *ABCC3* Polymorphism Genotypes        Study                                 Parameter                             Morphine                 Morphine-3-Glucuronide Formation   Morphine-6-Glucuronide Formation
  ------------------------------------- ------------------------------------- ------------------------------------- ------------------------ ---------------------------------- ----------------------------------
  rs4793665\                            T&A                                   ΔCL[\#](#TFN7){ref-type="table-fn"}   0.066 \[−0.022;0.153\]   0.55 \[0.18;0.92\]                 0.51 \[0.042;0.974\]
  CC vs CT+TT                                                                                                                                                                   

                                                                                                                                                                                

  ΔOFV[!](#TFN6){ref-type="table-fn"}   −1.73                                 −**16.46**                            −**7.73**                                                   

                                                                                                                                                                                

  Spine                                 ΔCL[\#](#TFN7){ref-type="table-fn"}   \-                                    0.55                     0.37                               

  \-                                    \[0.21;1.0\]                          \[0.11; 0.63\]                                                                                    

                                                                                                                                                                                

  ΔOFV[!](#TFN6){ref-type="table-fn"}   \-                                    −**9.1**                              −**8.09**                                                   

                                                                                                                                                                                

  rs4148412\                            T&A                                   ΔCL[\#](#TFN7){ref-type="table-fn"}   −0.04 \[−0.142;0.058\]   0.31 \[−0.65;0.02\]                0.255 \[−0.16;0.67\]
  AA vs. GG+AG                                                                                                                                                                  

                                                                                                                                                                                

  ΔOFV[!](#TFN6){ref-type="table-fn"}   −0.686                                −**5.833**                            −2.11                                                       

                                                                                                                                                                                

  Spine                                 ΔCL[\#](#TFN7){ref-type="table-fn"}   \-                                    0.45                     0.215                              

  \-                                    \[−0.04;0.95\]                        \[−0.185;0.615\]                                                                                  

                                                                                                                                                                                

  ΔOFV[!](#TFN6){ref-type="table-fn"}   \-                                    −3.53                                 −1.54                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ΔOFV = OFV~Cov~ - OFV~NoCov~; OFV=Objective Function Value

mean \[95%CI\]

ΔOFV \< −3.84 was considered to be statistically significant (p\<0.05) and are highlighted in bold.
